The expression of the inhibitory immune checkpoints PD-L1 and VISTA may explain the poor responsiveness of prostate cancer patients to CTLA-4 blockade and supports the design of a combination therapy targeting both molecules. Here, CTLA4 is linked to prostate cancer.